Page last updated: 2024-11-05

glymidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Glymidine is a sulfonylurea antidiabetic agent that was once used for treating type 2 diabetes. It acts by stimulating the release of insulin from the pancreas, thereby lowering blood glucose levels. Glymidine was synthesized and studied in the mid-20th century, but it has since been largely replaced by newer sulfonylurea drugs with better tolerability and efficacy. Glymidine's importance lies in its contribution to the development of the sulfonylurea class of antidiabetic medications. Research on glymidine provided valuable insights into the mechanism of action of these drugs and paved the way for the development of more effective treatments for type 2 diabetes. Glymidine is no longer widely studied due to the availability of newer and safer alternatives. However, it remains a subject of interest for researchers studying the history of antidiabetic drug development and the evolution of treatment strategies for type 2 diabetes.'

glymidine: was MH 1975-92 (see under SULFONAMIDES 1975-90); GLIDIAZINE & GLYCODIAZINE were see GLYMIDINE 1975-92; use SULFONAMIDES to search GLYMIDINE 1975-92; a sulfonamide hypoglycemic agent which stimulates insulin secretion [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

glymidine : A sulfonamide that is N-(pyrimidin-2-yl)benzenesulfonamide which is substituted at position 5 of the pyrimidine ring by a 2-methoxyethoxy group. It is a hypoglycemic drug used for the treatment of diabetes mellitus. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID9565
CHEMBL ID1697838
CHEBI ID146188
SCHEMBL ID34389
MeSH IDM0198145

Synonyms (44)

Synonym
339-44-6
glycodiazine
n-(5-{[2-(methyloxy)ethyl]oxy}pyrimidin-2-yl)benzenesulfonamide
brn 0552655
5-beta-(methoxyethoxy)-2-(phenylsulfonylamido)pyrimidine
benzenesulfonamide, n-(5-(2-methoxyethoxy)-2-pyrimidinyl)-
glymidinum
glycodiazin [german]
n-(5-(2-methoxyethoxy)-2-pyrimidinyl)benzenesulphonamide
einecs 206-426-5
2-benzolsulfonamido-5-beta-methoxy-aethoxy-pyrimidine [german]
n-(5-(2-methoxyethoxy)-2-pyrimidinyl)benzenesulfonamide
DB01382
glymidine
glidiazine
n-[5-(2-methoxyethoxy)pyrimidin-2-yl]benzenesulfonamide
2-benzenesulfonamido-5-(2-methoxyethoxy)pyrimidine
CHEBI:146188
CHEMBL1697838
glycodiazin
4c5i4bqz8f ,
unii-4c5i4bqz8f
2-benzolsulfonamido-5-beta-methoxy-aethoxy-pyrimidine
5-25-12-00549 (beilstein handbook reference)
glymidine [who-dd]
(n-(5-(2-methoxyethoxy)-2-pyrimidinyl)benzenesulfonamido)
glymidine [mi]
SCHEMBL34389
2-benzolsulfonylamino-5(beta-methoxy-athoxy)-pyrimidin
2-benzolsulfonamido-5-.beta.-methoxy-aethoxy-pyrimidine
QFWPJPIVLCBXFJ-UHFFFAOYSA-N
n-[5-(2-methoxyethoxy)-2-pyrimidinyl]benzenesulfonamide
5-.beta.-(methoxyethoxy)-2-(phenylsulfonylamido)pyrimidine
benzenesulfonamide, n-[5-(2-methoxyethoxy)-2-pyrimidinyl]-
iodicacid
DTXSID1023108
AKOS027327087
Q5572813
n-(5-(2-methoxyethoxy)pyrimidin-2-yl)benzenesulfonamide
SB58445
EX-A5946
HY-116844
EN300-22686192
CS-0066673
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
hypoglycemic agentA drug which lowers the blood glucose level.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
pyrimidinesAny compound having a pyrimidine as part of its structure.
sulfonamideAn amide of a sulfonic acid RS(=O)2NR'2.
dietherA polyether in which the number of ether linkages is 2.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1124588Hypoglycemic activity in rat at 9.6 to 150 mg/kg, iv measured after 3 hrs by GOD-Perid method1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Blood glucose lowering sulfonamides with asymmetric carbon atoms. 3. Related N-substituted carbamoylbenzoic acids.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID1124587Hypoglycemic activity in iv dosed rat measured after 1 hr by GOD-Perid method1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Blood glucose lowering sulfonamides with asymmetric carbon atoms. 3. Related N-substituted carbamoylbenzoic acids.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (55.56)18.7374
1990's2 (22.22)18.2507
2000's2 (22.22)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.47

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.47 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.23 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.47)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (10.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (90.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]